RLMD - NASDAQ

Relmada Therapeutics, Inc.

RLMD·NASDAQ

$6.38

-0.62%

HealthcareBiotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$467.87M

EPS-1.4500

P/E Ratio-4.40

Earnings Date08/06/2026

94.00M

Assets

105%

3Y-39.0%

5Y-20.0%

10Y+3214.0%

7.49M

Total Liabilities

-27%

3Y-40.0%

5Y-41.0%

10Y+444.0%

86.51M

Total Equity

144%

3Y-38.0%

5Y-18.0%

10Y+5824.0%

Relmada Therapeutics, Inc. Funding & Solvency Profile

RLMD · NASDAQ

Current Assets

Cash & Cash Equivalents3.50M

Net Receivables0.00

Inventory0.00

Other Current Assets0.00

Total Current Assets94 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets19.50K

Total Non-Current Assets20 K

Total Assets

94.00M

Financial Health Analysis

Current Ratio

14.62x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

88 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Relmada Therapeutics, Inc. Balance Sheet

RLMD • NASDAQ

Relmada Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Jun 2019	Jun 2018	Jun 2017	Jun 2016	Jun 2015	Jun 2014	Aug 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3.5M	3.9M	4.1M	5.4M	44.4M	2.5M	36.3M	9.2M	2.2M	1.7M	8.5M	22.5M	25.6M	8.9K
Short-Term Investments	89.5M	41.1M	92.2M	142.9M	167.5M	114.6M	80.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	93M	44.9M	96.3M	148.3M	211.9M	117.1M	116.4M	9.2M	2.2M	1.7M	8.5M	22.5M	25.6M	8.9K
Net Receivables	0.0	0.0	0.0	512.4K	86.4K	79.5K	73.1K	247.1K	72.1K	291.9K	0.0	0.0	0.0	0.0
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	291.9K	0.0	0.0	0.0	0.0
Other Receivables	0.0	0.0	0.0	512.4K	86.4K	79.5K	73.1K	247.1K	72.1K	0.0	263.3K	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	459K	426.9K	472.5K	534.8K	1.4M	0.0	6.4K
Prepaids	977.7K	886.5K	1.2M	4M	11.3M	903.2K	423.9K	520.7K	426.9K	347.3K	578K	1.5M	178.2K	0.0
Other Current Assets	0.0	0.0	0.0	0.0	35.0	-10.0	46.0	0.0	0.0	125.2K	231.9K	710.1K	0.0	3K
Total Current Assets	94M	45.8M	97.5M	152.9M	223.3M	118.1M	116.9M	10M	2.7M	2.5M	9.3M	24M	25.7M	18.4K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	0.0	0.0	0.0	0.0	1.3K	5K	7.2K	12.1K	2.3K	531.3K	23.9K	9.8K	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	203.1K	273.2K	337.7K	390.8K	390.8K	0.0	0.0
Other Non-Current Assets	19.5K	22K	43.1K	34.9K	28.3K	111.4K	191K	25K	24.8K	22K	23.6K	10K	12.1K	0.0
Total Non-Current Assets	19.5K	22K	43.1K	34.9K	28.3K	112.6K	196K	235.4K	310.1K	362K	945.7K	424.7K	21.9K	0.0
Total Assets	94M	45.8M	97.6M	152.9M	223.3M	118.2M	117.1M	10.2M	3M	2.8M	10.2M	24.4M	25.8M	18.4K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.6M	4.1M	3.5M	5.3M	11.2M	8.3M	522.7K	924.4K	765.4K	529.6K	1.3M	835.3K	746.1K	7K
Accounts Payable	1.6M	4.1M	3.5M	5.3M	11.2M	8.3M	522.7K	924.4K	765.4K	529.6K	1.3M	835.3K	746.1K	7K
Accrued Expenses	0.0	5M	3M	6.2M	2.2M	2.5M	574.9K	1.3M	48K	56.9K	634.9K	482.2K	382K	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	110.2K	364.2K	285.2K	276.7K	273.7K	263.8K	58.4K	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3M	659.5K	394.6K	634.9K	482.2K	382K	0.0
Other Current Liabilities	4.9M	1.2M	5.7M	1M	1.6M	1.8M	250K	-45.0	4.8M	513.6K	892.5K	14M	25.6M	0.0
Total Current Liabilities	6.4M	10.3M	12.2M	12.5M	15.1M	12.6M	1.5M	2.6M	5.9M	1.4M	3.1M	15.6M	26.8M	7K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	91K	0.0	0.0	0.0
Other Non-Current Liabilities	1.1M	4.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	140.9K	0.0	100K	0.0
Total Non-Current Liabilities	1.1M	4.5K	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	0.0	140.9K	0.0	100K	0.0
Total Liabilities	7.5M	10.3M	12.2M	12.5M	15.1M	12.6M	1.5M	2.6M	8.6M	1.4M	3.2M	15.6M	26.9M	7K
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	72.0	3.3K	0.0
Common Stock	73.3K	30.2K	30.1K	30.1K	27.7K	16.3K	14.5K	9.7K	3.1K	12.5K	12K	10.8K	40.3K	23.5K
Additional Paid-In Capital	784.7M	676.4M	646.2M	602.5M	513.3M	284.9M	235.5M	119.3M	88.8M	86.8M	86.1M	84.9M	16M	0.0
Retained Earnings	-698.3M	-640.9M	-560.9M	-462.1M	-305.1M	-179.3M	-119.9M	-111.7M	-94.3M	-85.4M	-79.1M	-76.1M	-55.3M	-12.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-456.0	0.0	9.4K	0.0	0.0	0.0	39.3M	0.0
Total Stockholders' Equity	86.5M	35.5M	85.4M	140.4M	208.3M	105.6M	115.7M	7.6M	-5.5M	1.5M	7M	8.8M	-55.3M	11.4K
Total Equity	86.5M	35.5M	85.4M	140.4M	208.3M	105.6M	115.7M	7.6M	-5.5M	1.5M	7M	8.8M	-55.3M	11.4K
SUMMARY
Total Liabilities & Equity	94M	45.8M	97.6M	152.9M	223.3M	118.2M	117.1M	10.2M	3M	2.8M	10.2M	24.4M	26.9M	18.4K
Total Investments	89.5M	41.1M	92.2M	142.9M	167.5M	114.6M	80.2M	203.1K	273.2K	337.7K	390.8K	390.8K	0.0	0.0
Total Debt	0.0	0.0	0.0	0.0	0.0	0.0	110.2K	364.2K	2.9M	276.7K	273.7K	263.8K	58.4K	0.0
Net Debt	-3.5M	-3.9M	-4.1M	-5.4M	-44.4M	-2.5M	-36.2M	-8.9M	702.7K	-1.4M	-8.2M	-22.2M	-25.5M	-8.9K
Shares Outstanding	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622	33,191,622

SEC Filings

RLMD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	May 27, 2026	2026	View Filing
S-3 S-3 N/A	April 03, 2026	April 03, 2026		View Filing
8-K 8-K 2026 N/A	March 20, 2026	March 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 15, 2025	December 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 13, 2025	November 13, 2025	2025	View Filing

Showing 1 to 10 of 232 filings

Related Guides

Blog Categories

Continue your RLMD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.